Theravance Biopharma (FRA:0TB) FCF Margin % : -7.67% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Theravance Biopharma's Free Cash Flow for the three months ended in Mar. 2024 was €-1.02 Mil. Theravance Biopharma's Revenue for the three months ended in Mar. 2024 was €13.34 Mil. Therefore, Theravance Biopharma's FCF Margin % for the quarter that ended in Mar. 2024 was -7.67%.

As of today, Theravance Biopharma's current FCF Yield % is -6.17%.

The historical rank and industry rank for Theravance Biopharma's FCF Margin % or its related term are showing as below:

FRA:0TB' s FCF Margin % Range Over the Past 10 Years
Min: -1525.17 Med: -361.49 Max: -48.15
Current: -48.15

During the past 12 years, the highest FCF Margin % of Theravance Biopharma was -48.15%. The lowest was -1525.17%. And the median was -361.49%.

FRA:0TB's FCF Margin % is ranked better than
62.62% of 1046 companies
in the Biotechnology industry
Industry Median: -145.305 vs FRA:0TB: -48.15

Theravance Biopharma FCF Margin % Historical Data

The historical data trend for Theravance Biopharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma FCF Margin % Chart

Theravance Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-328.78

-357.68

-381.96

-365.29

-51.34

Theravance Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-116.72	-96.64	-15.98	-8.72	-7.67

Competitive Comparison of Theravance Biopharma's FCF Margin %

For the Biotechnology subindustry, Theravance Biopharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theravance Biopharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's FCF Margin % falls into.

Theravance Biopharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Theravance Biopharma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-27.037	/	52.658
	=	-51.34 %

Theravance Biopharma's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-1.024	/	13.343
	=	-7.67 %

Theravance Biopharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Theravance Biopharma (FRA:0TB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (FRA:0TB) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

TBPH:USA

Address

Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104

Website

https://www.theravance.com

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma (FRA:0TB) Headlines

No Headlines